Clinical Trial Update: Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update indicates Regor Pharmaceuticals' investigational drug RGT-490 is being studied in a Phase 1 trial for patients with PIK3CA-mutated ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• RGT-490

Snippet

Sponsor: Regor Pharmaceuticals Inc. | Conditions: Breast Cancer, Ovarian Cancer | Phase 1 | Status: RECRUITING